Genetically determined debrisoquine oxidation capacity in bladder cancer

Publisher Website
Google Scholar
Abstract
A report is given of a series of bladder cancer cases examined for the oxidation capacity demonstrated by the use of debrisoquine [an antihypertensive agent, used as a carcinogen model]. No overall association of poor and extensive metabolizer exists between bladder cancer patients and a control group. An absolute association between a benzidine exposed subgroup and metabolizer status exists, but the numbers are too small to indicate the true nature of this relationship.